Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Key takeaways from ESMO 2022 in brain metastases

Ariane Steindl • 12 Sep 2022
ESMO 2022
Brain Tumor General Trastuzumab deruxtecan

Ariane Steindl, PhD, Medical University of Vienna, Vienna, Austria, reflects on key updates from the European Society for Medical Oncology (ESMO) 2022 Congress, including quality of life data of trastuzumab deruxtecan, highlighting the importance of safety and toxicity. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ariane Steindl

1:07
Recent advances in the systemic treatment of brain metastases
Ariane Steindl • 12 Sep 2022
3:04
Overall survival of brain-only oligometastatic patients with cancer
Ariane Steindl • 12 Sep 2022

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals